Psychedelic therapies are becoming mainstream. Deutsche Bank thinks this drug developer could triple

This biopharma play with two key drugs for treatment-resistant depression could see its stock rise by more than 230%, according to a Deutsche Bank analyst.

Please follow us:

This post was originally published here